trending Market Intelligence /marketintelligence/en/news-insights/trending/GJj2jt3E4SFxdp7-sJntlA2 content esgSubNav
In This List

CSPC Pharmaceutical subsidiary receives approval to list in Shenzhen

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


CSPC Pharmaceutical subsidiary receives approval to list in Shenzhen

Hong Kong-listed CSPC Pharmaceutical Group Ltd. said it received approval from the China Securities Regulatory Commission to list CSPC XNW Pharmaceutical Joint Stock Company Ltd and its subsidiaries on Chinext, a Nasdaq-style board of the Shenzhen Stock Exchange.

CSPC XNW is an indirect non-wholly owned subsidiary of CSPC that manufactures and sells caffeine, vitamin C health supplements, and beverage products.

The listing is subject to obtaining formal written approval and other processes.